Article
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2016
Lacouture M E, Keefe D M, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty J P, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon E B
Abstract excerpt
BACKGROUND: ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.